CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization
CD8+ T cells have the potential to control HSV-2 infection. However, limited information has been available on CD8+ T cell epitopes or the functionality of antigen specific T cells during infection or following immunization with experimental vaccines. Peptide panels from HSV-2 proteins ICP27, VP22 a...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2013-01-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2073-4409/2/1/19 |
| _version_ | 1797720609752350720 |
|---|---|
| author | Rebecca J. Platt Tansi Khodai Tim J. Townend Helen H. Bright Paul Cockle Luis Perez-Tosar Rob Webster Brian Champion Timothy P. Hickling Fareed Mirza |
| author_facet | Rebecca J. Platt Tansi Khodai Tim J. Townend Helen H. Bright Paul Cockle Luis Perez-Tosar Rob Webster Brian Champion Timothy P. Hickling Fareed Mirza |
| author_sort | Rebecca J. Platt |
| collection | DOAJ |
| description | CD8+ T cells have the potential to control HSV-2 infection. However, limited information has been available on CD8+ T cell epitopes or the functionality of antigen specific T cells during infection or following immunization with experimental vaccines. Peptide panels from HSV-2 proteins ICP27, VP22 and VP13/14 were selected from in silico predictions of binding to human HLA-A*0201 and mouse H-2Kd, Ld and Dd molecules. Nine previously uncharacterized CD8+ T cell epitopes were identified from HSV-2 infected BALB/c mice. HSV-2 specific peptide sequences stabilized HLA-A*02 surface expression with intermediate or high affinity binding. Peptide specific CD8+ human T cell lines from peripheral blood lymphocytes were generated from a HLA-A*02+ donor. High frequencies of peptide specific CD8+ T cell responses were elicited in mice by DNA vaccination with ICP27, VP22 and VP13/14, as demonstrated by CD107a mobilization. Vaccine driven T cell responses displayed a more focused immune response than those induced by viral infection. Furthermore, vaccination with ICP27 reduced viral shedding and reduced the clinical impact of disease. In conclusion, this study describes novel HSV-2 epitopes eliciting strong CD8+ T cell responses that may facilitate epitope based vaccine design and aid immunomonitoring of antigen specific T cell frequencies in preclinical and clinical settings. |
| first_indexed | 2024-03-12T09:23:01Z |
| format | Article |
| id | doaj.art-36be04601f7c43699028a04cc143f155 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-12T09:23:01Z |
| publishDate | 2013-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-36be04601f7c43699028a04cc143f1552023-09-02T14:24:28ZengMDPI AGCells2073-44092013-01-0121194210.3390/cells2010019CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And CharacterizationRebecca J. PlattTansi KhodaiTim J. TownendHelen H. BrightPaul CockleLuis Perez-TosarRob WebsterBrian ChampionTimothy P. HicklingFareed MirzaCD8+ T cells have the potential to control HSV-2 infection. However, limited information has been available on CD8+ T cell epitopes or the functionality of antigen specific T cells during infection or following immunization with experimental vaccines. Peptide panels from HSV-2 proteins ICP27, VP22 and VP13/14 were selected from in silico predictions of binding to human HLA-A*0201 and mouse H-2Kd, Ld and Dd molecules. Nine previously uncharacterized CD8+ T cell epitopes were identified from HSV-2 infected BALB/c mice. HSV-2 specific peptide sequences stabilized HLA-A*02 surface expression with intermediate or high affinity binding. Peptide specific CD8+ human T cell lines from peripheral blood lymphocytes were generated from a HLA-A*02+ donor. High frequencies of peptide specific CD8+ T cell responses were elicited in mice by DNA vaccination with ICP27, VP22 and VP13/14, as demonstrated by CD107a mobilization. Vaccine driven T cell responses displayed a more focused immune response than those induced by viral infection. Furthermore, vaccination with ICP27 reduced viral shedding and reduced the clinical impact of disease. In conclusion, this study describes novel HSV-2 epitopes eliciting strong CD8+ T cell responses that may facilitate epitope based vaccine design and aid immunomonitoring of antigen specific T cell frequencies in preclinical and clinical settings.http://www.mdpi.com/2073-4409/2/1/19HSV-2CD8+ epitopevaccineinfection |
| spellingShingle | Rebecca J. Platt Tansi Khodai Tim J. Townend Helen H. Bright Paul Cockle Luis Perez-Tosar Rob Webster Brian Champion Timothy P. Hickling Fareed Mirza CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization Cells HSV-2 CD8+ epitope vaccine infection |
| title | CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization |
| title_full | CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization |
| title_fullStr | CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization |
| title_full_unstemmed | CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization |
| title_short | CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization |
| title_sort | cd8 t lymphocyte epitopes from the herpes simplex virus type 2 icp27 vp22 and vp13 14 proteins to facilitate vaccine design and characterization |
| topic | HSV-2 CD8+ epitope vaccine infection |
| url | http://www.mdpi.com/2073-4409/2/1/19 |
| work_keys_str_mv | AT rebeccajplatt cd8tlymphocyteepitopesfromtheherpessimplexvirustype2icp27vp22andvp1314proteinstofacilitatevaccinedesignandcharacterization AT tansikhodai cd8tlymphocyteepitopesfromtheherpessimplexvirustype2icp27vp22andvp1314proteinstofacilitatevaccinedesignandcharacterization AT timjtownend cd8tlymphocyteepitopesfromtheherpessimplexvirustype2icp27vp22andvp1314proteinstofacilitatevaccinedesignandcharacterization AT helenhbright cd8tlymphocyteepitopesfromtheherpessimplexvirustype2icp27vp22andvp1314proteinstofacilitatevaccinedesignandcharacterization AT paulcockle cd8tlymphocyteepitopesfromtheherpessimplexvirustype2icp27vp22andvp1314proteinstofacilitatevaccinedesignandcharacterization AT luispereztosar cd8tlymphocyteepitopesfromtheherpessimplexvirustype2icp27vp22andvp1314proteinstofacilitatevaccinedesignandcharacterization AT robwebster cd8tlymphocyteepitopesfromtheherpessimplexvirustype2icp27vp22andvp1314proteinstofacilitatevaccinedesignandcharacterization AT brianchampion cd8tlymphocyteepitopesfromtheherpessimplexvirustype2icp27vp22andvp1314proteinstofacilitatevaccinedesignandcharacterization AT timothyphickling cd8tlymphocyteepitopesfromtheherpessimplexvirustype2icp27vp22andvp1314proteinstofacilitatevaccinedesignandcharacterization AT fareedmirza cd8tlymphocyteepitopesfromtheherpessimplexvirustype2icp27vp22andvp1314proteinstofacilitatevaccinedesignandcharacterization |